NEWS & RESOURCES
Estrigenix in the news
Estrigenix Therapeutics Announces Series Seed Financing to Advance ERβ Platform Across Women’s Health and Neurodegenerative Diseases
MILWAUKEE (July 21, 2026) — Estrigenix Therapeutics today announced the first closing of its $2M Series Seed financing, led by Talents Fund I. The financing provides the resources to advance its proprietary selective estrogen receptor-beta (ERβ) platform through translational preclinical development.The announcement follows several recent milestones in the company’s evolution,…
Estrigenix Therapeutics Secures Exclusive License Agreement for Novel Menopause Therapeutics Platform
MILWAUKEE (June 30, 2026) — Estrigenix Therapeutics, Inc., together with the University of Wisconsin–Milwaukee Research Foundation, Inc. (UWMRF), Marquette University, and CU Ventures, Inc., today announced the execution of an exclusive license agreement supporting the development of a novel therapeutic platform designed to address the mental and physical effects of menopause….
Estrigenix Therapeutics, Inc. presents at 2nd ACE Drug Discovery Summit 2024 in London
MILWAUKEE (March 21, 2024) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company leading the way in estrogen biology, is proud to have been a presenter at the ACE Drug Discovery Summit 2024 in London. William Donaldson, Ph.D., chief executive officer (CEO) of Estrigenix presented an abstract entitled, “Discovery…
Estrigenix invited to present at the Science2Startup Symposium in Boston, April 10th
MILWAUKEE (March 8, 2024) – Estrigenix Therapeutics, Inc., was selected to speak at Science2Startup symposium in Boston on April 10th. The Symposium is an invitation-only event focused on bringing academic innovations to the attention of the Boston-based venture capital ecosystem. Estrigenix was selected as one of eight teams to present,…
CSO Karyn Frick discusses “Why women are more likely to develop Alzheimer’s Disease” on Chicago radio WLS 890AM (the Big 89)
MILWAUKEE (October 25, 2023) – Estrigenix Therapeutics, Inc., a Wisconsin-based, privately held pharmaceutical company is leading the way in estrogen biology. Karyn Frick, Ph.D, chief scientific officer of Estrigenix spoke with Rob Johnson and Jane Clauss of Chicago radio “The Big 89” regarding Alzheimer’s Disease and the increased risk for…
Estrigenix Therapeutics to Attend The Menopause Society Meeting
MILWAUKEE (Sept. 22, 2023) – Estrigenix Therapeutics, Inc., is announcing Patricia Scheller, Executive Chairwoman, and Daniel Sem, VP for Business Development will attend the The Menopause Society, (formerly known at the North American Menopause Society) Annual Meeting in Philadelphia September 27 – 30, 2023. The Menopause Society is the premier…